230 related articles for article (PubMed ID: 31783313)
21. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
23. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
24. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Fostira F; Saloustros E; Apostolou P; Vagena A; Kalfakakou D; Mauri D; Tryfonopoulos D; Georgoulias V; Yannoukakos D; Fountzilas G; Konstantopoulou I
Breast Cancer Res Treat; 2018 May; 169(1):105-113. PubMed ID: 29335925
[TBL] [Abstract][Full Text] [Related]
25. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
Sundararajan S; Ahmed A; Goodman OB
Clin Adv Hematol Oncol; 2011 Oct; 9(10):748-55. PubMed ID: 22252577
[TBL] [Abstract][Full Text] [Related]
26. Germline BRCA mutation in male carriers-ripe for precision oncology?
Leão RRN; Price AJ; James Hamilton R
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
[TBL] [Abstract][Full Text] [Related]
27. Screening for familial and hereditary prostate cancer.
Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
[TBL] [Abstract][Full Text] [Related]
28. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
29. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
30. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
[TBL] [Abstract][Full Text] [Related]
31. Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls.
Momozawa Y; Iwasaki Y; Hirata M; Liu X; Kamatani Y; Takahashi A; Sugano K; Yoshida T; Murakami Y; Matsuda K; Nakagawa H; Spurdle AB; Kubo M
J Natl Cancer Inst; 2020 Apr; 112(4):369-376. PubMed ID: 31214711
[TBL] [Abstract][Full Text] [Related]
32. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Sinclair CS; Berry R; Schaid D; Thibodeau SN; Couch FJ
Cancer Res; 2000 Mar; 60(5):1371-5. PubMed ID: 10728701
[TBL] [Abstract][Full Text] [Related]
34. Familial prostate cancer.
Giri VN; Beebe-Dimmer JL
Semin Oncol; 2016 Oct; 43(5):560-565. PubMed ID: 27899188
[TBL] [Abstract][Full Text] [Related]
35. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
36. Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
Connors LM
Clin J Oncol Nurs; 2019 Feb; 23(1):32-35. PubMed ID: 30681994
[TBL] [Abstract][Full Text] [Related]
37. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
38. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
Brandão A; Paulo P; Teixeira MR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
[TBL] [Abstract][Full Text] [Related]
39. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
Vietri MT; D'Elia G; Caliendo G; Resse M; Casamassimi A; Passariello L; Albanese L; Cioffi M; Molinari AM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916521
[TBL] [Abstract][Full Text] [Related]
40. [Update on genetic predisposition to prostate cancer].
Cussenot O; Cancel-Tassin G
Bull Cancer; 2015 Jan; 102(1):53-6. PubMed ID: 25609482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
